Epstein-barr virus-associated posttransplant lymphoproliferative disorder of donor origin after simultaneous pancreas-kidney transplantation limited to pancreas allograft

American Journal of Transplantation

Volumn 6, Issue 10, 2006, Pages 2506-2511

  Rehbinder, B ^a   Wullstein, Ch ^a   Bechstein, W O ^a   Probst, M ^a   Engels, K ^a   Kriener, S ^a   Dobert N ^a   Schwarz, W ^a   Brixner, V ^b   Steffan, D ^a   Gauer, S ^a   Geiger, H ^a   Hauser, I A ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

B cell lymphoma; CD20; Ganciclovir; Microsatellite analysis; Rituximab; Transplantectomy

Indexed keywords

ANTIVIRUS AGENT; CD20 ANTIGEN; CYCLOSPORIN; GANCICLOVIR; IMMUNOGLOBULIN M; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB;

ADULT; ALLOTRANSPLANTATION; ANAMNESIS; ARTICLE; B CELL LYMPHOMA; CASE REPORT; CLINICAL EXAMINATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DONOR; EPSTEIN BARR VIRUS; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; KIDNEY PANCREAS TRANSPLANTATION; LABORATORY TEST; LYMPHOPROLIFERATIVE DISEASE; MALE; PANCREAS; PHYSICAL EXAMINATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROPHYLAXIS; SEROLOGY; SYMPTOMATOLOGY; UREMIA;

ADULT; BIOPSY; BURKITT LYMPHOMA; DIABETES MELLITUS, TYPE 1; DIAGNOSIS, DIFFERENTIAL; DNA, VIRAL; FOLLOW-UP STUDIES; HERPESVIRUS 4, HUMAN; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PANCREAS TRANSPLANTATION; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED; TRANSPLANTATION, HOMOLOGOUS;

EID: 33748518654     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01464.x     Document Type: Article

References (18)

1. Opelz G, Dohler B. Lymphomas after solid organ transplantation: A collaborative transplant study report. Am J Transplant 2004; 4: 222-230.
2. Andreone P, Gramenzi A, Lorenzini S et al. Posttransplantation lymphoproliferative disorders. Arch Intern Med 2003; 163: 1997-2004.
3. Cockfield SM. Identifying the patient at risk for post-transplant lymphoproliferative disorder. Transpl Infect Dis 2001; 3: 70-78.
4. Trofe J, Buell JF, Beebe TM et al. Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: The Israel Penn International Transplant Tumor Registry experience. Am J Transplant 2005; 5: 775-780.
5. Petit B, Le MY, Jaccard A et al. Influence of host-recipient origin on clinical aspects of posttransplantation lymphoproliferative disorders in kidney transplantation. Transplantation 2002; 73: 265-271.
6. Beck O, Seidl C, Lehrnbecher T et al. Quantification of chimerism within peripheral blood, bone marrow and purified leukocyte subsets: Comparison of singleplex and multiplex PCR amplification of short tandem repeat (STR) loci. Eur J Haematol 2006; 76: 237-244.
7. Bustami RT, Ojo AO,Wolfe RA et al. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant 2004; 4: 87-93.
8. European best practice guidelines for renal transplantation (part 1). Nephrol Dial Transplant 2000;15: 1-85.
9. Pirsch JD, Stratta RJ, Sollinger HW et al. Treatment of severe Epstein-Barr virus-induced lymphoproliferative syndrome with ganciclovir: Two cases after solid organ transplantation. Am J Med 1989; 86: 241-244.
10. Ng IO, Shek TW, Thung SN et al. Microsatellite analysis in post-transplantation lymphoproliferative disorder to determine donor/recipient origin. Mod Pathol 2000; 13: 1180-1185.
11. Weissmann DJ, Ferry JA, Harris NL, Louis DN, Delmonico F, Spiro I. Posttransplantation lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin. Am J Clin Pathol 1995; 103: 748-755.
12. Paraskevas S, Coad JE, Gruessner A et al. Posttransplant lymphoproliferative disorder in pancreas transplantation: A single-center experience. Transplantation 2005; 80: 613-622.
13. Meador TL, Krebs TL, Cheong JJ, Daly B, Keay S, Bartlett S. Imaging features of posttransplantation lymphoproliferative disorder in pancreas transplant recipients. AJR Am J Roentgenol 2000; 174: 121-124.
14. Cibeira MT, Lopez-Guillermo A, Colomer D et al. Diffuse large B-cell lymphoma arising from donor lymphoid cells after renal and pancreatic transplantation. Ann Hematol 2003; 82: 131-135.
15. Oertel SH, Anagnostopoulos I, Bechstein WO, Liehr H, Riess HB. Treatment of posttransplant lymphoproliferative disorder with the anti-CD20 monoclonal antibody rituximab alone in an adult after liver transplantation: A new drug in therapy of patients with post-transplant lymphoproliferative disorder after solid organ transplantation? Transplantation 2000; 69: 430-432.
16. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242.
17. Choquet S, Leblond V, Herbrecht R et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: Results of a prospective multicenter phase 2 study. Blood 2006; 107: 3053-3057.
18. Hanto DW. Retransplantation after post-transplant lymphoproliferative diseases (PTLD): When is it safe? Am J Transplant 2004; 4: 1733-1734.